Close Menu

NEW YORK – Gritstone Oncology announced Thursday morning that Phase I data for its new neoantigen therapy showed the treatment to be well-tolerated in patients. In addition, the investigators found that the neoantigens seemed to provoke strong immune responses in four solid tumor patients. The results were presented at the European Society for Medical Oncology Immuno-Oncology Congress in Geneva, Switzerland. 

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by

This webinar will discuss a single-center prospective interventional study that evaluated the success of a targeted therapy selected by profiling of ctDNA and tissue in patients with advanced and refractory carcinoma.